title: Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment.
abstract: There are limited data on the safety and efficacy of immunotherapy for patients with advanced pancreatic cancer (APC). A meta-analysis of single-arm trials is proposed to assess the efficacy and safety of immunotherapy for APC. Eighteen relevant studies involving 527 patients were identified. The pooled disease control rate (DCR), overall survival (OS), progression free survival (PFS), and 1-year survival rate were estimated as 59.32%, 7.90 months, 4.25 months, and 30.12%, respectively. Subgroup analysis showed that the pooled OS, PFS, and 1-year survival rate were significantly higher for autologous activated lymphocyte therapy compared with peptide-based vaccine therapy (OS: 8.28 months vs. 7.40 months; PFS: 6.04 months vs. 3.86 months; 1-year survival rate: 37.17% vs. 19.74%). Another subgroup analysis demonstrated that the pooled endpoints were estimated as obviously higher for immunotherapy plus chemotherapy compared with immunotherapy alone (DCR: 62.51% vs. 47.63%; OS: 8.67 months vs. 4.91 months; PFS: 4.91 months vs. 3.34 months; 1-year survival rate: 32.32% vs. 21.43%). Of the included trials, seven trials reported no treatment related adverse events , five trials reported (16.6 ± 3.9) % grade 3 adverse events and no grade 4 adverse events. In conclusion, immunotherapy is safe and effective in the treatment of APC.
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.|Graduate College, Southern Medical University, Guangzhou, Guangdong, P.R. China.
authors.forename: Bin
authors.initials: B
authors.lastname: Zhang
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.|Graduate College, Southern Medical University, Guangzhou, Guangdong, P.R. China.
authors.forename: Yuhao
authors.initials: Y
authors.lastname: Dong
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.|Graduate College, Southern Medical University, Guangzhou, Guangdong, P.R. China.
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.|Graduate College, Southern Medical University, Guangzhou, Guangdong, P.R. China.
authors.forename: Zhouyang
authors.initials: Z
authors.lastname: Lian
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.|Graduate College, Southern Medical University, Guangzhou, Guangdong, P.R. China.
authors.forename: Long
authors.initials: L
authors.lastname: Liang
authors.affiliation: Department of Radiology, Huizhou Municipal Central Hospital, Huizhou, Guangdong, P.R. China.
authors.forename: Wenbo
authors.initials: W
authors.lastname: Chen
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.|Graduate College, Southern Medical University, Guangzhou, Guangdong, P.R. China.
authors.forename: Xiaoning
authors.initials: X
authors.lastname: Luo
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.|Graduate College, Southern Medical University, Guangzhou, Guangdong, P.R. China.
authors.forename: Shufang
authors.initials: S
authors.lastname: Pei
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.|Graduate College, Southern Medical University, Guangzhou, Guangdong, P.R. China.
authors.forename: Xiaokai
authors.initials: X
authors.lastname: Mo
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.|Graduate College, Southern Medical University, Guangzhou, Guangdong, P.R. China.
authors.forename: Lu
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.|School of medicine, South China University of Technology, Guangzhou, Guangdong, P.R. China.
authors.forename: Wenhui
authors.initials: W
authors.lastname: Huang
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.|Graduate College, Southern Medical University, Guangzhou, Guangdong, P.R. China.
authors.forename: Fusheng
authors.initials: F
authors.lastname: Ouyang
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.|Graduate College, Southern Medical University, Guangzhou, Guangdong, P.R. China.
authors.forename: Baoliang
authors.initials: B
authors.lastname: Guo
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.
authors.forename: Changhong
authors.initials: C
authors.lastname: Liang
authors.affiliation: Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China.
authors.forename: Shuixing
authors.initials: S
authors.lastname: Zhang
mesh_terms: D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004358:Drug Therapy; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D017710:Lymphocyte Transfusion / Q000009:adverse effects / Q000379:methods*; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines
keywords: advanced pancreatic cancer; adverse events; chemotherapy; immunotherapy; overall survival